Cargando…
Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling
The development of new therapeutic agents against the coronavirus causing Middle East Respiratory Syndrome (MERS) is a continuing imperative. The initial MERS-CoV epidemic was contained entirely through public health measures, but episodic cases continue, as there are currently no therapeutic agents...
Autores principales: | Lee, Hyun, Ren, Jinhong, Pesavento, Russell P., Ojeda, Isabel, Rice, Amy J., Lv, Haining, Kwon, Youngjin, Johnson, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6638567/ https://www.ncbi.nlm.nih.gov/pubmed/30940566 http://dx.doi.org/10.1016/j.bmc.2019.03.050 |
Ejemplares similares
-
Inhibitor Recognition Specificity of MERS-CoV Papain-like
Protease May Differ from That of SARS-CoV
por: Lee, Hyun, et al.
Publicado: (2015) -
Structural and functional characterization of MERS coronavirus papain-like protease
por: Lin, Min-Han, et al.
Publicado: (2014) -
Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease
por: Clasman, Jozlyn R., et al.
Publicado: (2020) -
MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
por: Mielech, Anna M., et al.
Publicado: (2014) -
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
por: Lin, Min-Han, et al.
Publicado: (2018)